89bio, Inc.
ETNB
$8.47
$0.293.55%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.95% | 22.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.70% | 184.34% | |||
| Operating Income | 19.70% | -184.34% | |||
| Income Before Tax | 20.67% | -211.20% | |||
| Income Tax Expenses | 25.98% | 52.24% | |||
| Earnings from Continuing Operations | 20.61% | -210.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.61% | -210.76% | |||
| EBIT | 19.70% | -184.34% | |||
| EBITDA | 19.70% | -184.39% | |||
| EPS Basic | 26.68% | -189.74% | |||
| Normalized Basic EPS | 25.45% | -190.15% | |||
| EPS Diluted | 26.68% | -189.74% | |||
| Normalized Diluted EPS | 25.45% | -190.15% | |||
| Average Basic Shares Outstanding | 8.29% | 7.26% | |||
| Average Diluted Shares Outstanding | 8.29% | 7.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
